Deferred Tax Assets, Valuation Allowance of Prelude Therapeutics Inc from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Prelude Therapeutics Inc quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Prelude Therapeutics Inc Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $211,904,000, a 16% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Prelude Therapeutics Inc Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $211,904,000 +$29,262,000 +16% 31 Dec 2025 10-K 10 Mar 2026 2025 FY
Q4 2024 $182,642,000 +$35,026,000 +24% 31 Dec 2024 10-K 10 Mar 2026 2025 FY
Q4 2023 $147,616,000 +$36,563,000 +33% 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q4 2022 $111,053,000 +$35,682,000 +47% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q4 2021 $75,371,000 +$42,472,000 +129% 31 Dec 2021 10-K 15 Mar 2023 2022 FY
Q4 2020 $32,899,000 +$17,490,000 +114% 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q4 2019 $15,409,000 31 Dec 2019 10-K 16 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.